Survival Comparisons Between Early Male and Female Breast Cancer Patients

Wang, Kang; Wang, Qiu Juan; Xiong, Yong; Shi, Yang; Yang, Wen; Zhang, Xiang; Li, Hong Yuan

doi:10.1038/s41598-018-26199-6

Cited by 8 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At our knowledge, other published studies 26 , 27 carried out propensity score matching to adjust potential confounding factors. In the series of Wang et al 28 their balanced group had a ratio of approximately two FBC to every MBC, and showed a Ten Years OS of 58.3%, with FBC with superior OS than MBC even after matching, in contrast with our findings.…”

Section: Discussioncontrasting

confidence: 91%

Comparison between male and female breast cancer survival using propensity score matching analysis

Scomersi

Giudici

Cacciatore

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Male breast cancer (MBC) is a rare disease. The few studies on MBC reported conflicting data regarding survival outcomes compared to women. This study has two objectives: to describe the characteristics of a single-cohort of MBC and to compare overall survival (OS) and disease-free survival (DFS) between men and women using the propensity score matching (PSM) analysis. We considered MBC patients (n = 40) diagnosed between January 2004 and May 2019. Clinical, pathological, oncological and follow-up data were analyzed. Univariate analysis was performed to determine the prognostic factors on OS and DFS for MBC. We selected female patients with BC (n = 2678). To minimize the effect of the imbalance of the prognostic factors between the two cohorts, the PSM method (1:3 ratio) was applied and differences in survival between the two groups were assessed. The average age of MBC patients was 73 years. The 5-year OS and DFS rates were 76.7% and 72.2% respectively. The prognostic factors that significantly influenced OS and DFS were tumor size and lymph node status. After the PSM, 5 year-OS was similar between MBC and FBC (72.9% vs 72.3%, p = 0.70) while we found a worse DFS for MBC (72.2% vs 91.4%, p = 0.03). Our data confirmed previous reported MBC characteristics: we found a higher risk of recurrence in MBC compared to FMC but similar OS. MBC and FMC are different entities and studies are needed to understand its epidemiology and guide its management.

show abstract

Section: Discussioncontrasting

confidence: 91%

Comparison between male and female breast cancer survival using propensity score matching analysis

Scomersi

Giudici

Cacciatore

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Most of the studies have demonstrated that the median age at diagnosis of MBC is 68 years, which is 5–10 years older than that of women when diagnosed with breast cancer (12). Moreover, black men were at a higher risk of MBC than other races (30, 31). Also, MBC patients who had undergone surgery and radiotherapy have a better prognosis (31).…”

Section: Discussionmentioning

confidence: 95%

“…Moreover, black men were at a higher risk of MBC than other races (30, 31). Also, MBC patients who had undergone surgery and radiotherapy have a better prognosis (31). The findings of our analysis are consistent with these previous reports.…”

Section: Discussionmentioning

confidence: 95%

Development and Validation of a Nomogram for Predicting Survival in Male Patients With Breast Cancer

et al. 2019

View full text Add to dashboard Cite

Male breast cancer (MBC) is rare, and most patients are diagnosed at an advanced stage. We aimed to develop a reliable nomogram to predict breast cancer-specific survival (BCSS) for MBC patients, thus helping clinical diagnosis and treatment. Based on data from the Surveillance, Epidemiology, and End Results (SEER) database, 2,451 patients diagnosed with MBC from 2010 to 2015 were selected for this study. They were randomly assigned to either a training cohort ( n = 1715) or a validation cohort ( n = 736). The Multivariate Cox proportional hazards regression analysis was used to determine the independent prognostic factors, which were then utilized to build a nomogram for predicting 3- and 5-year BCSS. The discrimination and calibration of the new model was evaluated using the Concordance index (C-index) and calibration curves, while its accuracy and benefits were assessed by comparing it to the traditional AJCC staging system using the net reclassification improvement (NRI), the integrated discrimination improvement (IDI), and the decision curve analysis (DCA). Multivariate models revealed that age, AJCC stage, ER status, PR status, and surgery all showed a significant association with BCSS. A nomogram based on these variables was constructed to predict survival in MBC patients. Compared to the AJCC stage, the C-index (training group: 0.840 vs. 0.775, validation group: 0.818 vs. 0.768), the areas under the receiver operating characteristic curve of the training set (3-year AUC: 0.852 vs. 0.778, 5-year AUC: 0.841 vs. 0.774) and the validation set (3-year AUC: 0.778 vs. 0.752, 5-year AUC: 0.852 vs. 0.794), and the calibration plots of this model all exhibited better performance. Additionally, the NRI and IDI confirmed that the nomogram was a great prognosis tool. Finally, the 3- and 5-year DCA curves yielded larger net benefits than the traditional AJCC stage. In conclusion, we have successfully established an effective nomogram to predict BCSS in MBC patients, which can assist clinicians in determining the appropriate therapy strategies for individual male patients.

show abstract

“…Moreover, superior discriminatory capacity was observed in our nomogram compared to the SEER or TNM staging classification, with respect to OS prediction. Two other studies have also established prognostic nomograms for MBC (Sun et al, 2019; Wang et al, 2018). Sun et al (2019) established a nomogram for predicting breast cancer-specific death and other cause-specific deaths of non-metastatic MBC.…”

Section: Discussionmentioning

confidence: 99%

“…Wang et al also established a nomogram for predicting the OS of early breast cancer patients (T 1−2 N 0−2 M 0 ). They found that age, marital status, grade, T stage, N stage, ER, surgery, chemotherapy, and radiation therapy were independent prognostic factors of OS (Wang et al, 2018). The results of their study are basically consistent with our findings; however, there are still differences between the two studies in the patients included.…”

Section: Discussionmentioning

confidence: 99%

A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery

Chai¹,

Sun²,

Jia

et al. 2019

PeerJ

View full text Add to dashboard Cite

Objective The study was designed to construct and validate a nomogram for predicting overall survival (OS) of male breast cancer (MBC) patients with infiltrating duct carcinoma (IDC). Methods The cohort was selected from the Surveillance, Epidemiology, and End Results (SEER) database between January 1, 2004 and December 31, 2013. Univariate and multivariate Cox proportional hazard (PH) regression models were performed. A nomogram was developed based on the significant prognostic indicators of OS. The discriminatory and predictive capacities of nomogram were assessed by Harrell’s concordance index (C-index), calibration plots, area under the curve (AUC) and the decision curve analysis (DCA). Results The median and maximal survival time of 1862 eligible patients were 49 and 131 months, respectively. Multivariate analysis showed that age (P < 0.0001), marital status (P = 0.002), T stage (P < 0.0001), N stage (P = 0.021), M stage (P < 0.0001), progesterone receptor (PR) (P = 0.046), human epidermal growth factor receptor-2 (HER2) (P = 0.009), and chemotherapy (P = 0.003) were independent prognostic indicators of IDC of MBC. The eight variables were then combined to construct a 3-and 5-year nomogram. The C-indexes of the nomogram were0.740 (95% confidence interval [CI] [0.709–0.771]) and 0.718 (95% CI [0.672–0.764]) for the internal validation and external validation, respectively. A better discriminatory capacity was observed in the nomogram compared with the SEER summary stage (P < 0.001) and AJCC TNM staging systems (6th edition; P < 0.001) with respect to OS prediction. Good consistency was detected between the nomogram prediction and actual findings, as indicated by calibration curves. The AUC for 3-and 5-year OS was 0.739 (95% CI [0.693–0.786]) and 0.764 (95% CI [0.725–0.803]) in the training cohort and 0.737 (95% CI [0.671–0.803]) and 0.735 (95% CI [0.678–0.793]) in the validation cohort, respectively. The DCA demonstrated that the survival nomogram was clinically useful. Conclusions The nomogram was able to more accurately predict 3-and 5-year OS of MBC patients with IDC histology than were existing models.

show abstract

Survival Comparisons Between Early Male and Female Breast Cancer Patients

Cited by 8 publications

References 43 publications

Comparison between male and female breast cancer survival using propensity score matching analysis

Comparison between male and female breast cancer survival using propensity score matching analysis

Development and Validation of a Nomogram for Predicting Survival in Male Patients With Breast Cancer

A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery

Contact Info

Product

Resources

About